Rifampin, Rifapentine, and Rifabutin Are Active against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus epidermidis.

Antimicrobial Agents and Chemotherapy
Cody Fisher, Robin Patel

Abstract

Staphylococcus epidermidis is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant S. epidermidis isolates. Compared to no treatment, treatment resulted in a ≥2-fold log10 reduction of intracellular rifampin-susceptible, but not rifampin-resistant, S. epidermidis These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated S. epidermidis.

References

Nov 28, 2006·Best Practice & Research. Clinical Rheumatology·Werner Zimmerli
Mar 20, 2010·Tuberculosis·Paul A AristoffH D Showalter
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas R OsmonUNKNOWN Infectious Diseases Society of America
Apr 4, 2014·Clinical Microbiology Reviews·Aaron J Tande, Robin Patel
Apr 22, 2015·Clinical Orthopaedics and Related Research·Carlos J SanchezJoseph C Wenke
Dec 31, 2017·International Journal of Antimicrobial Agents·Yu Mi WiRobin Patel
Aug 1, 2018·Infection and Immunity·Kimberly Perez, Robin Patel

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.